Six months after Apple unveiled the Studio Display XDR with built-in medical imaging capabilities, the FDA clearance required to use those features in clinical settings remains publicly unresolved. Apple disclosed the pending status at launch — a rare act of regulatory transparency — yet has issued no follow-up, leaving a $3,299 monitor caught between what its hardware promises and what the law permits. In the long arc of technology entering medicine, this moment reflects a familiar tension: innovation moves at the speed of engineering, while trust in clinical tools is earned at the pace of in